Janssen Pharmaceutica Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Janssen Pharmaceutica Inc.
In a new landmark, Chinese firm BeiGene has posted greater quarterly sales of its cancer drug Brukinsa in the US than in China for the first time. Meanwhile, a growing number of innovative products developed in China are on the cusp of expansion into overseas markets.
As India gets set to resume COVID-19 vaccine diplomacy from October, a new rule which will require Indians visiting UK who are fully vaccinated with AstraZeneca partner Serum Institute’s vaccine to undergo quarantine has sparked a row. Meanwhile, Indian companies await a nod from the WHO for wider acceptance of their COVID-19 vaccines.
Anne Carpenter, one of In Vivo’s 2021 Rising Leaders, talks about the growth of open source technology, putting data into action and why pharma deserves to be rewarded for evolving academic findings into marketable products for patients.
The WHO indicates that several claim applications have been made under the COVAX no-fault lump-sum compensation program for COVID-19 vaccines. It remains to be seen how the scheme may apply to countries like India, which is also expected to take a call on indemnity to vaccine makers.